PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma

被引：84

作者：

Gomez-Abad, Cristina ^{[1
]}

Pisonero, Helena ^{[1
,2
]}

Blanco-Aparicio, Carmen ^{[3
]}

Roncador, Giovanna ^{[4
]}

Gonzalez-Menchen, Alberto ^{[5
]}

Martinez-Climent, Jose A. ^{[6
]}

Mata, Eva ^{[1
]}

Elena Rodriguez, Maria ^{[1
]}

Munoz-Gonzalez, Guillermo ^{[1
]}

Sanchez-Beato, Margarita ^{[1
]}

Leal, Juan F. ^{[3
]}

Bischoff, James R. ^{[3
]}

Piris, Miguel A. ^{[1
,2
]}

机构：

[1] Spanish Natl Canc Ctr CNIO, Lymphoma Grp, Mol Pathol Programme, E-28049 Madrid, Spain

[2] Hosp Univ Marques Valdecilla, Inst Formac Invest Marques de Valdecilla, Santander, Spain

[3] CNIO, Expt Therapeut Programme, Madrid, Spain

[4] CNIO, Monoclonal Antibodies Unit, Biotechnol Programme, Madrid, Spain

[5] Hosp Reina Sofia, Cordoba, Spain

[6] Fdn Appl Med Res, Oncol Div, Ctr Invest Med Aplicada, Navarra, Spain

来源：

BLOOD | 2011年 / 118卷 / 20期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; KINASE INHIBITORS; CYCLE PROGRESSION; TRANSGENIC MICE; TUMOR-GROWTH; C-MYC; PROTEIN; PHOSPHORYLATES; EXPRESSION; SURVIVAL;

D O I：

10.1182/blood-2011-03-344374

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PIM serine/threonine kinases are over-expressed, translocated, or amplified in multiple B-cell lymphoma types. We have explored the frequency and relevance of PIM expression in different B-cell lymphoma types and investigated whether PIM inhibition could be a rational therapeutic approach. Increased expression of PIM2 was detected in subsets of mantle cell lymphoma, diffuse large B-cell lymphoma (DLBLC), follicular lymphoma, marginal zone lymphoma-mucosa-associated lymphoid tissue type, chronic lymphocytic leukemia, and nodal marginal zone lymphoma cases. Increased PIM2 protein expression was associated with an aggressive clinical course in activated B-like-DLBCL patients. Pharmacologic and genetic inhibition of PIM2 revealed p4E-BP1(Thr37/46) and p4E-BP1(Ser65) as molecular biomarkers characteristic of PIM2 activity and indicated the involvement of PIM2 kinase in regulating mammalian target of rapamycin complex 1. The simultaneous genetic inhibition of all 3 PIM kinases induced changes in apoptosis and cell cycle. In conclusion, we show that PIM2 kinase inhibition is a rational approach in DLBCL treatment, identify appropriate biomarkers for pharmacodynamic studies, and provide a new marker for patient stratification. (Blood. 2011;118(20):5517-5527)

引用

页码：5517 / 5527

页数：11

共 51 条

[1] Functional signatures identified in B-cell non-Hodgkin lymphoma profiles [J].

Aggarwal, Mohit ;

Sanchez-Beato, Margarita ;

Gomez-Lopez, Gonzalo ;

Al-Shahrour, Fatima ;

Martinez, Nerea ;

Rodriguez, Antonia ;

Ruiz-Ballesteros, Elena ;

Camacho, Francisca I. ;

Perez-Rosado, Alberto ;

de la Cueva, Paloma ;

Artiga, Maria J. ;

Pisano, David G. ;

Kimby, Eva ;

Dopazo, Joaquin ;

Villuendas, Raquel ;

Piris, Miguel A. .

LEUKEMIA & LYMPHOMA, 2009, 50 (10) :1699-1708

[2] Pim-1 kinase promotes inactivation of the pro-apoptotic bad protein by phosphorylating it on the Ser112 gatekeeper site [J].

Aho, TLT ;

Sandholm, J ;

Peltola, KJ ;

Mankonen, HP ;

Lilly, M ;

Koskinen, PJ .

FEBS LETTERS, 2004, 571 (1-3) :43-49

[3] Synthesis, Kinase Inhibitory Potencies, and in Vitro Antiproliferative Evaluation of New Pim Kinase Inhibitors [J].

Akue-Gedu, Rufine ;

Rossignol, Emilie ;

Azzaro, Stephane ;

Knapp, Stefan ;

Filippakopoulos, Panagis ;

Bullock, Alex N. ;

Bain, Jenny ;

Cohen, Philip ;

Prudhomme, Michelle ;

Anizon, Fabrice ;

Moreau, Pascale .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (20) :6369-6381

[4] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[5] The survival kinases Akt and Pim as potential pharmacological targets [J].

Amaravadi, R ;

Thompson, CB .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2618-2624

[6] THE HUMAN PROTOONCOGENE PRODUCT P33PIM IS EXPRESSED DURING FETAL HEMATOPOIESIS AND IN DIVERSE LEUKEMIAS [J].

AMSON, R ;

SIGAUX, F ;

PRZEDBORSKI, S ;

FLANDRIN, G ;

GIVOL, D ;

TELERMAN, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8857-8861

[7]

[Anonymous], 2008, WHO CLASSIFICATION T

[8]

[Anonymous], NAT GENET

[9]

[Anonymous], 1958, J AM STAT ASSOC, DOI [DOI 10.1080/01621459.1958.10501452, DOI 10.2307/2281868]

[10] The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C [J].

Bachmann, M ;

Kosan, C ;

Xing, PX ;

Montenarh, M ;

Hoffmann, I ;

Möröy, T .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (03) :430-443

← 1 2 3 4 5 6 →